title: Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study).
abstract: The first Phase I Trial with a combination of IL-2 and IFN-alpha was published in 1989. There are still some questions though, concerning the in vivo effects of this combination on lymphocytes. We designed a prospective pilot study to evaluate in vivo effects of low dose IL-2 and IFN-alpha combination on expression of Bcl-2, FAS (Apo-1/CD 95), Fas Ligand, IL-2 receptor (CD25), and HLA-DR on peripheral lymphocytes in patients with advanced renal cell carcinoma. After initiation of the immunomodulating therapy, Bcl-2 expressing lymphocytes increased significantly on day 3 (p < 0.025), Fas (Apo-1/CD95) expressing lymphocyte increased significantly on day 5 (p < 0.003), Fas ligand expressing lymphocytes increased significantly on day 3 (p < 0.004), HLA-DR expressing lymphocytes increased significantly on day 5 (p < 0.003), and IL-2 receptor (CD25) expressing cells increased significantly on day 5 (p < 0.01). We conclude that immunomodulating therapy induces in vivo expression of Bcl-2, Fas (Apo-1) and Fas Ligand in lymphocytes significantly.
authors.affiliation: University of Istanbul, Cerrahpasa School of Medicine, Medical Oncology Department, Turkey. gdemir@turknet
authors.forename: G
authors.initials: G
authors.lastname: Demir
authors.forename: M
authors.initials: M
authors.lastname: Ozguroglu
authors.forename: N
authors.initials: N
authors.lastname: Sayhan
authors.forename: N
authors.initials: N
authors.lastname: Molinas-Mandel
authors.forename: F
authors.initials: F
authors.lastname: Demirelli
authors.forename: E
authors.initials: E
authors.lastname: Buyukunal
authors.forename: N
authors.initials: N
authors.lastname: Tuzuner
authors.forename: S
authors.initials: S
authors.lastname: Serdengecti
authors.forename: B
authors.initials: B
authors.lastname: Berkarda
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D053222:Fas Ligand Protein; D005260:Female; D006684:HLA-DR Antigens / Q000096:biosynthesis; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000556:secondary; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis*; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013997:Time Factors; D019014:fas Receptor / Q000096:biosynthesis*
chemical_list: D000276:Adjuvants, Immunologic; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D006684:HLA-DR Antigens; D016898:Interferon-alpha; D007376:Interleukin-2; D008562:Membrane Glycoproteins; D019253:Proto-Oncogene Proteins c-bcl-2; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D019014:fas Receptor